{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Edwards NC"],"funding":["NICHD NIH HHS","NCATS NIH HHS","National Centralized Repository for Alzheimer's Disease and Related Dementias","NIA NIH HHS","DS-Connect (The Down Syndrome Registry) supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","NIHR Cambridge Biomedical Research Centre and the Windsor Research Unit, CPFT, Fulbourn Hospital Cambridge","National Institutes of Health programs: The Alzheimer's Disease Research Centers program"],"pagination":["e70726"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12475832"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(10)"],"pubmed_abstract":["Introduction
Despite having few vascular risk factors, people with Down syndrome (DS) have MRI evidence of cerebrovascular disease (CVD) and neuroinflammation that worsens with Alzheimer's disease (AD) severity. We investigated whether markers of CVD and inflammation are associated with AD-related diagnostic progression in people with DS.Methods
We included 149 participants (mean age [SD] = 44.6 [9]) from the Alzheimer's Biomarkers Consortium-Down Syndrome who had two (n = 24) or three follow-up visits (n = 125). We derived white matter hyperintensity (WMH) volume and plasma biomarker (glial fibrillary acidic protein [GFAP], amyloid beta [Aβ]42/Aβ40, hyperphosphorylated tau-217 [p-tau217], and neurofilament light [NfL]) concentrations at baseline and examined their associat"],"journal":["Alzheimer's & dementia : the journal of the Alzheimer's Association"],"pubmed_title":["Alzheimer's disease diagnostic progression is associated with cerebrovascular disease and neuroinflammation in adults with Down syndrome."],"pmcid":["PMC12475832"],"funding_grant_id":["U24 AG21886","P50 AG008702","UL1 TR002373","UL1 TR001873","UL1 TR002345","P30 AG062421","U54 HD087011","UL1 TR001414","RF1 AG079519","P50 AG005681","P50 HD105353","U19 AG068054","F31 AG090091","P50 AG005133","P30 AG066519","P30 AG062715","UL1 TR001857","U24 AG021886","U01 AG051412","U01 AG051406","P50 AG16537","U54 HD090256"],"pubmed_authors":["Rizvi B","Simoes S","Zaman S","O'Bryant S","Lai F","Petersen ME","Wilcock DM","Brickman AM","Rosas HD","Edwards NC","Gutierrez J","Lott IT","Handen BL","Lao PJ","Lee JH","Mapstone M","Alshikho MJ","Janelidze S","Alzheimer's Biomarkers Consortium–Down Syndrome (ABC‐DS) Investigators","Christian BT","Hansson O","Flores-Aguilar L","Tudorascu DL","Ericsson OM","Yassa MA","Head E"],"additional_accession":[]},"is_claimable":false,"name":"Alzheimer's disease diagnostic progression is associated with cerebrovascular disease and neuroinflammation in adults with Down syndrome.","description":"Introduction
Despite having few vascular risk factors, people with Down syndrome (DS) have MRI evidence of cerebrovascular disease (CVD) and neuroinflammation that worsens with Alzheimer's disease (AD) severity. We investigated whether markers of CVD and inflammation are associated with AD-related diagnostic progression in people with DS.Methods
We included 149 participants (mean age [SD] = 44.6 [9]) from the Alzheimer's Biomarkers Consortium-Down Syndrome who had two (n = 24) or three follow-up visits (n = 125). We derived white matter hyperintensity (WMH) volume and plasma biomarker (glial fibrillary acidic protein [GFAP], amyloid beta [Aβ]42/Aβ40, hyperphosphorylated tau-217 [p-tau217], and neurofilament light [NfL]) concentrations at baseline and examined their associat","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-03T23:31:19.863Z","creation":"2026-05-03T03:11:44.095Z"},"accession":"S-EPMC12475832","cross_references":{"pubmed":["41014048"],"doi":["10.1002/alz.70726"]}}